Pfizer's Strong Growth Prospects and Dividend Potential Make It an Attractive Investment Choice
Thursday, 9 May 2024, 08:37
Pfizer's Diversified Product Portfolio
Pfizer's new product lineup and strategic acquisitions position it for future dividend growth.
Revenue Performance
Revenue sunk year over year, but excluding COVID-19 product sales, total revenue rose significantly.
Patent Cliff Concerns
Pfizer outpaces patent cliffs by launching new drugs to offset losses, such as Eliquis and Padcev.
Dividend Growth Potential
With an ultra-high dividend yield and a strong pipeline, Pfizer is poised for dividend growth ahead.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.